Nobilis Therapeutics said today that it partnered with device manufacturer Submersible Systems to develop a portable, hand-held inhalation device that administers a xenon gas-based therapeutic, NBTX-001.
The companies said they are working on customizing and testing the drug-device combination. The group plans to pursue regulatory approval with the FDA, supported by upcoming clinical trials in PTSD, alzheimer’s, dementia and autism, see this here for more info.
Get the full story at our sister site, Drug Delivery Business News.